Haloperidol Richter (Haloperidol)

Haloperidol Richter is indicated for several psychiatric and neurological conditions where dopamine blockade is beneficial.

• Management of schizophrenia in adults.
• Treatment of acute psychotic episodes.
• Control of severe agitation associated with psychiatric disorders.
• Adjunct therapy for Tourette syndrome.
• Short‑term use in patients with severe behavioral disturbances.
• May be employed in other off‑label situations as determined by a healthcare professional.

Side effects of haloperidol can vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor or rigidity.
• Dry mouth.
• Constipation.
• Blurred vision.
• Weight gain.

Serious

• Tardive dyskinesia (involuntary movements).
• Neuroleptic malignant syndrome (fever, muscle rigidity).
• Severe hypotension.
• Cardiac arrhythmias (QT prolongation).
• Elevated prolactin levels causing hormonal changes.
• Seizures in predisposed individuals.

Before initiating Haloperidol Richter, clinicians should evaluate several safety considerations.

• Assess cardiovascular status, especially for QT interval prolongation.
• Monitor for signs of extrapyramidal symptoms and tardive dyskinesia.
• Use caution in patients with a history of seizures or epilepsy.
• Evaluate liver and renal function for dose adjustments.
• Discuss potential hormonal effects, such as hyperprolactinemia, with patients.
• Review any history of neuroleptic malignant syndrome.
• Consider pregnancy and lactation status; use only if benefits outweigh risks.

Haloperidol can interact with various medications, influencing its efficacy and safety profile.

Avoid

• Other dopamine antagonists that may increase extrapyramidal risk.
• Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors that can raise haloperidol plasma levels.

Use with caution

• CNS depressants such as benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents that can mask extrapyramidal symptoms.
• CYP2D6 substrates, as haloperidol may affect their metabolism.
• Lithium, due to potential additive neurotoxic effects.
• Alcohol, which can increase central nervous system depression.